



17 December 2008

Dr Eric Abadie
European Medicines Agency
7 Westferry Circus
Canary Wharf
London
E14 4HB
United Kingdom

Subject: Withdrawal of Advexin[®], (contusogene ladenovec), 2.2×10^{12} viral particles suspension for injection - EMEA/H/C/000919/0000

Dear Dr Abadie,

I would like to inform you that, at this point of time, Gendux Molecular Ltd has taken the decision to withdraw the application for Marketing Authorisation of Advexin, (contusogene ladenovec), 2.2×10^{12} viral particles suspension for injection, which was intended to be used for the treatment of Li-Fraumeni cancer in adults and adolescents from the age of 18 years as a monotherapy.

This withdrawal is based on the following reasons:

- The Company's marketing strategy – The Company wishes to apply its limited resources to other EMEA and global regulatory projects.

We reserve the right to make further submissions at a future date in this or other therapeutic indication(s).

I agree for this letter to be published on the EMEA website.

Yours sincerely,
Gendux Molecular Ltd

[Redacted signature block]